David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
MRD-status 1 jaar na stamceltransplantatie geassocieerd met overleving na 6 jaar
jun 2024 | MM, Stamceltransplantatie